R7 (drug)

R7
Clinical data
Other names4-Oxo-2-phenyl-4H-chromene-7,8-diyl bis(dimethylcarbamate)
Routes of
administration		By mouth[1]
Legal status
Legal status
Pharmacokinetic data
Bioavailability~35% (in mice)[2]
MetabolitesTropoflavin[1]
Elimination half-life~3.25 hours (in mice[2]
Identifiers
  • [8-(Dimethylcarbamoyloxy)-4-oxo-2-phenylchromen-7-yl] N,N-dimethylcarbamate
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC21H20N2O6
Molar mass396.399 g·mol−1
3D model (JSmol)
  • CN(C)C(=O)OC1=C(C2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3)OC(=O)N(C)C
  • InChI=1S/C21H20N2O6/c1-22(2)20(25)28-16-11-10-14-15(24)12-17(13-8-6-5-7-9-13)27-18(14)19(16)29-21(26)23(3)4/h5-12H,1-4H3
  • Key:KHUMQRAGNPGBIE-UHFFFAOYSA-N

R7 is a small-molecule flavonoid and orally active, potent, and selective agonist of the tropomyosin receptor kinase B (TrkB) – the main signaling receptor for the neurotrophin brain-derived neurotrophic factor (BDNF) – which is under development for the treatment of Alzheimer's disease.[1][3][2] It is a structural modification and prodrug of tropoflavin (7,8-DHF) with improved potency and pharmacokinetics, namely oral bioavailability and duration.[2]

  1. ^ a b c Liu C, Chan CB, Ye K (2016). "7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders". Translational Neurodegeneration. 5 (1): 2. doi:10.1186/s40035-015-0048-7. PMC 4702337. PMID 26740873.
  2. ^ a b c d US application 20150274692, Ye K, "7,8-Dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto", published 2015-10-01, assigned to Emory University. 
  3. ^ Kazim SF, Iqbal K (July 2016). "Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease". Molecular Neurodegeneration. 11 (1): 50. doi:10.1186/s13024-016-0119-y. PMC 4940708. PMID 27400746.